Skip to main content
Figure 1 | BMC Palliative Care

Figure 1

From: An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain

Figure 1

BPI questions 3, 4, 5, and 6: summary from baseline to subsequent months and end point (all patients). Baseline and months 1 to 12 = absolute values; end point = last observation carried forward. Participating patient numbers - pain at its worst: n = 65 at baseline, n = 10 at month 12, and n = 67 at end point; pain at its least: n = 66 at baseline, n = 10 at month 12, and n = 67 at end point; pain on average: n = 66 at baseline, n = 10 at month 12, and n = 67 at end point; current pain: n = 66 at baseline, n = 10 at month 12, and n = 67 at end point. BPI, brief pain inventory; SE, standard error.

Back to article page